ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 2049

Vaccination Coverage and Caregiver Perspectives for Children with Rheumatic Diseases Compared to Healthy Controls
Abstract Number: 2050

Variability in Vaccination Practices in Children with Rheumatic Diseases: Results of a Rheumatology Provider Childhood Arthritis and Rheumatology Research Alliance (CARRA)-wide Survey
Abstract Number: 2051

Screening Multisystem Inflammatory Syndrome in Children: Accuracy of SickKids Screening Pathway Compared to ACR Algorithm
Abstract Number: 2052

Risk Factors for Hospitalization for SARS-CoV-2 in Pediatric Patients with Rheumatic Diseases: A Systematic Review and Meta-analysis
Abstract Number: 2053

Predictive Factors Associated with Treatment Response in Chronic Nonbacterial Osteomyelitis
Abstract Number: 2054

Superiority of Adalimumab in Treating Childhood Chronic Idiopathic Uveitis: Evidence from a Multicentre Experience
Abstract Number: 2055

A Randomized Controlled Trial of Two Hepatitis a Vaccine Doses Among Adolescents with Juvenile Idiopathic Arthritis and Crohn’s Disease on Immunosuppressive Therapy: A Pilot Study
Abstract Number: 2056

Pediatric Acute-onset Neuropsychiatric Syndrome: Markers of Inflammation/autoimmunity at Clinical Presentation and Eventual Development of Arthritis and Other Autoimmune Diseases
Abstract Number: 2057

Medical Trauma and Its Association with Pain and Disability Risk in Children with Inflammatory Arthritis
Abstract Number: 2058

IL-1 Blocking Treatment Slows the Progression of Sensorineural Hearing Loss in Patients with NOMID
Abstract Number: 2059

Management of Iatrogenic, Recombinant Interleukin-1 Receptor Antagonist-type Amyloidosis on NOMID in Patients on Anakinra
Abstract Number: 2060

Creation of a Standardized and Collaborative Transfer Process from Pediatric to Adult Rheumatology
Abstract Number: 2061

Evaluation of a Tool to Enhance Training of the Physical Examination of the Temporomandibular Joint (TM Joint) in Juvenile Idiopathic Arthritis (JIA)
Abstract Number: 2062

A Mental Health Workshop for Pediatric Rheumatology Fellows
Abstract Number: 2063

Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY): Assessing Behavioral Predictors of Clinical Trial Referrals Among Healthcare Providers

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].